Samuel D. Rabkin
Molecular Neurosurgery Laboratory and the Brain Tumor Research Center,
Department of Neurosurgery,
Molecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery
Massachusetts General Hospital and Harvard Medical School
Samuel D. Rabkin has not added Biography.
If you are Samuel D. Rabkin and would like to personalize this page please email our Author Liaison for assistance.
Oncolytic herpes simplex virus vectors for cancer virotherapy.
Cancer gene therapy Dec, 2002 | Pubmed ID: 12522436
Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.
Cancer research Feb, 2005 | Pubmed ID: 15735042
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Molecular therapy : the journal of the American Society of Gene Therapy Dec, 2006 | Pubmed ID: 17045531
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2006 | Pubmed ID: 17121900
Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
Clinical cancer research : an official journal of the American Association for Cancer Research Oct, 2007 | Pubmed ID: 17908985
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.
Molecular therapy : the journal of the American Society of Gene Therapy Jun, 2008 | Pubmed ID: 18388912
Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.
Cancer research May, 2010 | Pubmed ID: 20424118
A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
Clinical cancer research : an official journal of the American Association for Cancer Research Jun, 2011 | Pubmed ID: 21505062
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2011 | Pubmed ID: 21976549
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Journal of the National Cancer Institute Jan, 2012 | Pubmed ID: 22173583
Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.
Journal of virology Apr, 2012 | Pubmed ID: 22345479
Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
Stem cells translational medicine Apr, 2012 | Pubmed ID: 23197811
Current status of gene therapy for brain tumors.
Translational research : the journal of laboratory and clinical medicine Apr, 2013 | Pubmed ID: 23246627
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.
Cell reports May, 2013 | Pubmed ID: 23707066
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
Proceedings of the National Academy of Sciences of the United States of America Jul, 2013 | Pubmed ID: 23754388
Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
Neuro-oncology Aug, 2014 | Pubmed ID: 24470552
Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.
Cell Apr, 2014 | Pubmed ID: 24726434
Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta.
Cancer cell international , 2014 | Pubmed ID: 25360068
Designing Herpes Viruses as Oncolytics.
Molecular therapy oncolytics , 2015 | Pubmed ID: 26462293
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.
Drugs of the future , 2015 | Pubmed ID: 26855472
Oncolytic herpes simplex virus interactions with the host immune system.
Current opinion in virology 12, 2016 | Pubmed ID: 27497296
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Cancer cell 08, 2017 | Pubmed ID: 28810147
Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade.
Oncoscience Jul, 2017 | Pubmed ID: 28966936
Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
Journal of virology 08, 2018 | Pubmed ID: 29793956
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
Molecular therapy oncolytics Jun, 2019 | Pubmed ID: 31016228
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.
Oncoimmunology , 2019 | Pubmed ID: 31143509
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
Nature communications 07, 2019 | Pubmed ID: 31266951
Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.
Acta neuropathologica communications 12, 2020 | Pubmed ID: 33308315
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved